Article
Rheumatology
Seher Sener, Veysel Cam, Ezgi Deniz Batu, Muserref Kasap Cuceoglu, Zeynep Balik, Emil Aliyev, Yagmur Bayindir, Ozge Basaran, Yelda Bilginer, Seza Ozen
Summary: This study aimed to establish a treatment management and discontinuation protocol for paediatric FMF patients treated with canakinumab. The protocol involved gradually reducing the frequency of canakinumab administration over time. Results showed that more than half of the patients were able to successfully discontinue canakinumab treatment within 18 months.
Article
Pediatrics
Burcu Bozkaya Yucel, Ozlem Aydog, Hulya Nalcacioglu, Aysegul Yilmaz
Summary: The study retrospectively analyzed 65 FMF patients who received canakinumab treatment due to colchicine resistance or intolerance. The results showed that canakinumab treatment was highly effective, well-tolerated in pediatric FMF patients, and controlled extension of the canakinumab dose interval was safe, with no severe adverse effects observed.
FRONTIERS IN PEDIATRICS
(2021)
Review
Rheumatology
Berkay Kilic, Yelin Guler, Feyza N. Azman, Ece Bostanci, Serdal Ugurlu
Summary: This study aimed to evaluate the efficacy and safety of anti-IL-1 agents in FMF patients. The results showed that anti-IL-1 agents significantly decreased levels of inflammatory markers and demonstrated good efficacy and low adverse events in adult and pediatric FMF patients.
Article
Medicine, General & Internal
Shuhei Yoshida, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Kiyoshi Migita
Summary: This study investigated the clinical features and treatment response of Japanese patients with FMF. It found that colchicine was effective in the majority of patients, but some patients showed resistance to colchicine. Canakinumab showed good efficacy in colchicine-resistant patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
B. Sozeri, H. E. Sonmez, S. G. Karadag, E. Baglan, K. Ozturk, M. Cakan, F. Demir, G. Otar Yener, S. Ozdel, N. Aktay Ayaz
Summary: The study suggests that withdrawing or extending the dose interval of canakinumab may be feasible in pediatric patients with colchicine-resistant familial Mediterranean fever. Some patients experienced new attacks after withdrawal, while others remained symptom-free.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Review
Medicine, General & Internal
B. H. Egeli, S. Ugurlu
Summary: As inflammation research improves, our understanding of autoinflammatory conditions also increases. Familial Mediterranean fever (FMF), being the entrance to this field, is still clinically relevant for our understanding of patient management, treatment options, and underlying mechanisms.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
(2022)
Review
Rheumatology
F. Kharouf, T. Tsemach-Toren, E. Ben-Chetrit
Summary: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease treated with colchicine, which has associated problems. Anti-interleukin-1 (anti-IL-1) agents may provide a more effective and safer alternative to colchicine therapy, as they are less likely to cause side effects and drug interactions.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Maddalena Lancieri, Marta Bustaffa, Serena Palmeri, Ignazia Prigione, Federica Penco, Riccardo Papa, Stefano Volpi, Roberta Caorsi, Marco Gattorno
Summary: This study provides an updated overview on the main aspects of pathophysiology, genetics, diagnosis, and treatment resistance of Familial Mediterranean Fever (FMF), a prototypal autoinflammatory disease. It also emphasizes the importance of FMF in understanding the functioning of the innate immune system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Rheumatology
Yusuf Karabulut, Halise Hande Gezer, Mehmet Tuncay Duruoez
Summary: This study presented the real-life experience of using canakinumab in adult patients with Familial Mediterranean fever resistant to standard therapy from two rheumatology clinics. The research found that canakinumab is effective and tolerable in reducing attacks in resistant FMF patients, suggesting it may be another treatment option for those who are non-responsive to colchicine and/or anakinra. Further studies with larger patient samples are needed to validate these findings.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Rheumatology
Yusuf Karabulut, Halise Hande Gezer, Nuran Oz, Irfan Esen, Mehmet Tuncay Duruoz
Summary: This study investigated the disease characteristics of FMF patients undergoing dose optimisation and discontinuation of canakinumab therapy. The results showed that canakinumab is a safe and effective treatment, and the dosing interval may be extended, allowing for follow-up without medication for eligible patients.
RHEUMATOLOGY INTERNATIONAL
(2022)
Review
Pharmacology & Pharmacy
Dimitri Poddighe, Micol Romano, Facundo Garcia-Bournissen, Erkan Demirkaya
Summary: Familial Mediterranean fever (FMF) is commonly diagnosed in childhood and is treated predominantly with colchicine, but in cases of intolerance or resistance, the use of biologics, especially interleukin-1 antagonists, should be considered.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pediatrics
Elif Kilic Konte, Fatih Haslak, Mehmet Yildiz, Neslihan Gucuyener, Ipek Ulkersoy, Aybuke Gunalp, Esma Aslan, Amra Adrovic, Sezgin Sahin, Kenan Barut, Ozgur Kasapcopur
Summary: This study aimed to investigate the demographic and clinical characteristics of children with both FMF and PFAPA syndromes and their response to colchicine and tonsillectomy. The results showed that patients with tonsillopharyngitis, aphthous stomatitis, and PFAPA family history were more likely to be colchicine-resistant and tonsillectomy responsive, while those with exon 10 MEFV gene mutations were more prone to have a favorable response to colchicine.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Review
Medicine, General & Internal
Xi Yin, Fangyuan Tian, Bin Wu, Ting Xu
Summary: The study evaluated the efficacy and safety of interventions for reducing inflammation in people with FMF, with findings suggesting that drugs like anakinra, rilonacept, canakinumab may be beneficial. However, limited randomized controlled trials contributed data for analysis.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Rheumatology
Takuya Tomokawa, Tomohiro Koga, Yushiro Endo, Toru Michitsuji, Atsushi Kawakami
Summary: This study suggests that canakinumab is effective and safe for use in Japanese patients with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF) in a real-world clinical setting in Japan.
MODERN RHEUMATOLOGY
(2022)
Article
Rheumatology
Fadi Kharouf, Yuval Ishay, Ariel Kenig, Menachem Bitan, Eldad Ben-Chetrit
Summary: The study found no significant difference in the odds of hospitalization for COVID-19 between FMF patients and the non-FMF population, and similar disease severity and therapeutic approach in FMF COVID-19 inpatients and matched non-FMF COVID-19 inpatients.
Article
Rheumatology
Yesim Ozguler, Gulen Hatemi, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Sermin Borekci, Ersan Atahan, Gul Ongen, Vedat Hamuryudan
RHEUMATOLOGY INTERNATIONAL
(2016)
Letter
Medicine, General & Internal
Sebahattin Yurdakul, Gizem Ayan, Yesim Ozguler, Gulen Hatemi, Serdal Ugurlu, Emire Seyahi, Hasan Yazici
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2017)
Article
Genetics & Heredity
Serdal Ugurlu, Aysa Hacioglu, Yasaman Adibnia, Vedat Hamuryudan, Huri Ozdogan
ORPHANET JOURNAL OF RARE DISEASES
(2017)
Article
Rheumatology
Taryn Youngstein, Patrycja Hoffmann, Ahmet Gul, Thirusha Lane, Rene Williams, Dorota M. Rowczenio, Huri Ozdogan, Serdal Ugurlu, John Ryan, Len Harty, Sean Riminton, Alex P. Headley, Joachim Roesler, Norbert Blank, Jasmin B. Kuemmerle-Deschner, Anna Simon, Adrian S. Woolf, Philip N. Hawkins, Helen J. Lachmann
Article
Rheumatology
Mert Oztas, Serdal Ugurlu, Ovgu Aydin
RHEUMATOLOGY INTERNATIONAL
(2017)
Article
Rheumatology
Sezgin Sahin, Amra Adrovic, Kenan Barut, Serdal Ugurlu, Eda Tahir Turanli, Huri Ozdogan, Ozgur Kasapcopur
RHEUMATOLOGY INTERNATIONAL
(2018)
Letter
Rheumatology
Ilker Karacan, Serdal Ugurlu, Sezgin Sahin, Elif Everest, Ozgur Kasapcopur, Aslihan Tolun, Huri Ozdogan, Eda Tahir Turanli
JOURNAL OF RHEUMATOLOGY
(2018)
Review
Medicine, General & Internal
Huri Ozdogan, Serdal Ugurlu
Article
Rheumatology
Ilker Karacan, Ayse Balamir, Serdal Ugurlu, Asli Kirectepe Aydin, Elif Everest, Seyit Zor, Merve Ozkilinc Onen, Selcuk Dasdemir, Ozan Ozkaya, Betul Sozeri, Abdurrahman Tufan, Deniz Gezgin Yildirim, Selcuk Yuksel, Nuray Aktay Ayaz, Rukiye Eker Omeroglu, Kubra Ozturk, Mustafa Cakan, Oguz Soylemezoglu, Sezgin Sahin, Kenan Barut, Amra Adrovic, Emire Seyahi, Huri Ozdogan, Ozgur Kasapcopur, Eda Tahir Turanli
RHEUMATOLOGY INTERNATIONAL
(2019)
Article
Rheumatology
M. Erdogan, S. Ugurlu, H. Ozdogan, E. Seyahi
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2019)
Review
Rheumatology
Gizem Ayan, Sinem Nihal Esatoglu, Gulen Hatemi, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Huri Ozdogan, Sebahattin Yurdakul, Vedat Hamuryudan
RHEUMATOLOGY INTERNATIONAL
(2018)
Article
Rheumatology
I. Karacan, S. Ugurlu, A. Tolun, E. Tahir Turanli, H. Ozdogan
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2017)
Article
Medicine, Research & Experimental
Abdulhalim Senyigit, Omur Tabak, Timur Orbanoglu, Aytac Karadag, Serdal Ugurlu, Hafize Uzun, Dihlar Konukoglu
CLINICAL AND INVESTIGATIVE MEDICINE
(2017)
Article
Clinical Neurology
Ugur Uygunoglu, Burcu Zeydan, Yesim Ozguler, Serdal Ugurlu, Emire Seyahi, Naci Kocer, Civan Islak, Kejal Kantarci, Sabahattin Saip, Aksel Siva, Orhun H. Kantarci
ANNALS OF NEUROLOGY
(2017)